AbbVie Just Announced 2 Big Acquisitions: Is This Dividend King a No-Brainer Buy Right Now?
Change the narrative: That's been a classic strategy for businesses facing stiff challenges. And it's a strategy that (NYSE: ABBV) appears to have pulled off successfully in recent days.
During 2023 investors have primarily focused on the company's declining revenue and profits, which stem from the loss of patent exclusivity for its top-selling autoimmune-disease drug Humira. AbbVie's share price reflected the concerns.
However, AbbVie just announced two big acquisitions, spurring its stock to rebound somewhat. Is this Dividend King now a no-brainer buy?
Source Fool.com
AbbVie Inc. Stock
€144.78
-1.220%
With 22 Buy predictions and not a single Sell prediction AbbVie Inc. is an absolute favorite of our community.
With a target price of 175 € there is a positive potential of 20.87% for AbbVie Inc. compared to the current price of 144.78 €.
